Oncogenic roles of the SETDB2 histone methyltransferase in gastric cancer

Area of Science:

• Molecular biology
• Cancer research
• Epigenetics

Background:

• SET domain bifurcated 2 (SETDB2) is a histone methyltransferase involved in gene silencing.
• Its role in carcinogenesis, particularly in gastric cancer (GC), remains largely unexplored.

Purpose of the Study:

• To investigate the alterations and functional significance of SETDB2 in human gastric cancers.
• To elucidate the molecular mechanisms underlying SETDB2's potential role in GC progression.

Main Methods:

• Immunohistochemistry to assess SETDB2 protein expression in GC tissues.
• Cell proliferation, migration, and invasion assays in GC cell lines with SETDB2 knockdown or overexpression.
• Analysis of global H3K9 tri-methylation (H3K9me3) levels.
• Microarray analysis to identify SETDB2-regulated genes.
• Chromatin immunoprecipitation (ChIP) assays to determine SETDB2 binding and H3K9me3 enrichment at target gene promoters.

Main Results:

• SETDB2 was overexpressed in 41.7% of primary GC tissues and associated with advanced stage and poor patient prognosis.
• SETDB2 modulation significantly affected GC cell proliferation, migration, and invasion.
• SETDB2 knockdown reduced global H3K9me3 levels and upregulated tumor suppressor genes WWOX and CADM1.
• SETDB2 was recruited to the promoters of WWOX and CADM1, leading to increased H3K9me3 and transcriptional repression.

Conclusions:

• SETDB2 overexpression contributes to gastric cancer progression.
• SETDB2 acts as an oncogene in GC by transcriptionally repressing tumor suppressors WWOX and CADM1 via H3K9me3 modification.